罗格列酮降低2型糖尿病大鼠血清糖基化终产物-肽和单核细胞趋化蛋白-1水平

Reduction of Serum Advanced Glycosylation End Products-Peptides and Monocyte Chemoattractant Protein-1 by Rosiglitazone in Type 2 Diabetic Rats

目的:观察马来酸罗格列酮对2型糖尿病大鼠血清糖基化终产物-肽(AGE-P)和单核细胞趋化蛋白-1(MCP-1)水平的影响。方法:腹腔注射小剂量链脲佐菌素结合高能量饲料制备2型糖尿病大鼠模型,分别接受马来酸罗格列酮、格列本脲治疗12周。运用流动注射分析法测定血清AGE-P,ELISA法测定血清MCP-1水平。结果:糖尿病大鼠血清AGE-P和MCP-1明显高于对照组,两者显著相关;药物治疗组血清AGE-P低于模型组但高于正常对照,罗格列酮组水平低于格列本脲组;罗格列酮组血清MCP-1低于模型组和格列本脲组。结论:糖尿病动物血清AGE-P和MCP-1升高,两者相互作用可能有助于糖尿病慢性并发症发生发展;降低血糖有助于降低血清AGE-P水平;罗格列酮具有超越降糖之外的降低血清AGE-P和MCP-1效应,可能具备更优的防治糖尿病慢性并发症作用。

AIM： To investigate the effect of rosiglitazone on the serum advanced glycosylation end products-peptide （AGE-P） and monocyte chemoattractant protein-1 （MCP-1） in type 2 diabetic rats. METHODS： Type 2 diabetic rats were induced by an intraperitoneal injection of low doses of streptozotocin combined with high fat diet, and were randomized to receive rosiglitazone, glibenclamide or vehicle treatment for 12 weeks. Serum AGE-P and MCP-1 were measured by using flow injection assay and ELISA, respectively. RESULTS： Serum AGE-P and MCP-1 concentration was significantly higher in diabetic rats compared to non-diabetic control, and serum AGE-P level shows a positive correlation with the MCP-1 concentration in diabetic rats. Serum AGE-P was significantly lower in diabetic rats treated with rosiglitazone and glibenclamide compared to untreated group but higher than non-diabetic control, while it was significantly higher in glibenclamide group compared to rosiglitazone group. Serum MCP-1 was significantly reduced in diabetic rats treated with rosiglitazone compared to glibenclamide and vehicle group. CONCLUSION：The present data demonstrated that the interaction between elevated AGE-P and MCP-1 might play a role in the development of diabetic complication. The reduction of serum AGE-P and MCP-1 observed after treatment with rosiglitazone might be attributable in part to an attenuation of diabetic vascular disease.